I really would like to have multiple supervisors. My supervisor is abroad and other prof.s are at dangers drawn. It's far worse than just feeling lonely... I'm research assistant, working under the heel of swore enemies

Title : Animal models of neuropsychiatric disorders
Authors : Eric J Nestler & Steven E Hyman
Journal : Nature Neuroscience
Publication Date : 2010
Citation : Nestler EJ, Hyman SE.Animal models of neuropsychiatric disorders.Nat Neurosci.2010;13(10):1161-9.
Direct Link : "http://www.nature.com/neuro/journal/v13/n10/full/nn.2647.html" (doi:10.1038/nn.2647)
Abstract :
Modeling of human neuropsychiatric disorders in animals is extremely challenging given the subjective nature of many symptoms, the lack of biomarkers and objective diagnostic tests, and the early state of the relevant neurobiology and genetics. Nonetheless, progress in understanding pathophysiology and in treatment development would benefit greatly from improved animal models. Here we review the current state of animal models of mental illness, with a focus on schizophrenia, depression and bipolar disorder. We argue for areas of focus that might increase the likelihood of creating more useful models, at least for some disorders, and for explicit guidelines when animal models are reported.

My thanks for your kindly aid.
It's perfectly working and this was just what i needed

Here it is :

Title : A safe lithium mimetic for bipolar disorder
Authors : Singh,N., Halliday, A.C., Thomas, J.M., et al.
Journal : Nature Communications
Publication Date : 2013
Citation : Singh N, Halliday AC, Thomas JM, et al. A safe lithium mimetic for bipolar disorder. Nat Commun. 2013;4:1332.
Direct Link : "http://www.nature.com/ncomms/journal/v4/n1/full/ncomms2320.html" (doi:10.1038/ncomms2320)
Abstract :
Lithium is the most effective mood stabilizer for the treatment of bipolar disorder, but it is toxic at only twice the therapeutic dosage and has many undesirable side effects. It is likely that a small molecule could be found with lithium-like efficacy but without toxicity through target-based drug discovery; however, therapeutic target of lithium remains equivocal. Inositol monophosphatase is a possible target but no bioavailable inhibitors exist. Here we report that the antioxidant ebselen inhibits inositol monophosphatase and induces lithium-like effects on mouse behaviour, which are reversed with inositol, consistent with a mechanism involving inhibition of inositol recycling. Ebselen is part of the National Institutes of Health Clinical Collection, a chemical library of bioavailable drugs considered clinically safe but without proven use. Therefore, ebselen represents a lithium mimetic with the potential both to validate inositol monophosphatase inhibition as a treatment for bipolar disorder and to serve as a treatment itself.